Potentiation of the cytotoxicity of peplomycin against Ehrlich ascites carcinoma by bleomycin hydrolase inhibitors.
D000818:Animals; D001761:Bleomycin / Q000008:administration & dosage*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D002470:Cell Survival / Q000187:drug effects; D003546:Cysteine Endopeptidases; D004357:Drug Synergism; D005260:Female; D006026:Glycoside Hydrolases / Q000037:antagonists & inhibitors*; D007930:Leucine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D007976:Leupeptins / Q000008:administration & dosage*; D051379:Mice; D009842:Oligopeptides / Q000008:administration & dosage*; D017663:Peplomycin
D007976:Leupeptins; D009842:Oligopeptides; D001761:Bleomycin; D017663:Peplomycin; D006026:Glycoside Hydrolases; D003546:Cysteine Endopeptidases; C031262:bleomycin hydrolase; D007930:Leucine; C032854:leupeptin; C024974:E 64